Abstract
Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies / analysis
-
Biological Assay
-
Bronchiolitis, Viral / microbiology
-
Bronchiolitis, Viral / therapy*
-
Humans
-
Infant
-
Interferon Type I / analysis
-
Interferon Type I / immunology
-
Interferon Type I / therapeutic use*
-
Pilot Projects
-
Respiratory Syncytial Viruses / drug effects
-
Respirovirus Infections / therapy*
Substances
-
Antibodies
-
Interferon Type I